Mesenchymal stromal cells for systemic sclerosis treatment |
| |
| Authors: | Dominique Farge Séverine Loisel Pauline Lansiaux Karin Tarte |
| |
| Institution: | 1. School of Information Technology in Education, South China Normal University, Guangzhou, China;2. Guangdong Engineering Research Center for Smart Learning, South China Normal University, Guangzhou, China;3. School of Computing and Mathematics, Charles Sturt University, Albury, Australia;4. Department of Computer Science, The University of Hong Kong, Hong Kong, China;5. Department of Systems Engineering and Engineering Management, The Chinese University of Hong Kong, Hong Kong, China;1. Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia 19107, USA;2. Sidney Kimmel Medical College, Thomas Jefferson University, USA;3. Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, USA;4. Division of Rheumatology, Department of Medicine, Thomas Jefferson University, USA;1. Department of Rheumatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa 41 110, Greece;2. Center for Molecular Medicine, Old Dominion University, Norfolk, VA, USA;3. Division of Transplantation Immunology and Mucosal Biology, Kings College School of Medicine, London SE5 9RS, UK |
| |
| Abstract: | Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterized by vasculopathy, dysregulation of innate and adaptive immune responses, and progressive fibrosis. SSc remains an orphan disease, with high morbity and mortality in SSc patients. The mesenchymal stromal cells (MSC) demonstrate in vitro and in vivo pro-angiogenic, immuno-suppressive, and anti-fibrotic properties and appear as a promising stem cell therapy type, that may target the key pathological features of SSc disease.This review aims to summarize acquired knowledge in the field of :1) MSC definition and in vitro and in vivo functional properties, which vary according to the donor type (allogeneic or autologous), the tissue sources (bone marrow, adipose tissue or umbilical cord) or inflammatory micro-environment in the recipient; 2) preclinical studies in various SSc animal models , which showed reduction in skin and lung fibrosis after MSC infusion; 3) first clinical trials in human, with safety and early efficacy results reported in SSc patients or currently tested in several ongoing clinical trials. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
